| 1 |
33907275 | The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. | 2021 Apr 27 |
1 |
| 2 |
33980863 | FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. | 2021 May 12 |
1 |
| 3 |
34101105 | HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib. | 2021 Dec |
6 |
| 4 |
33354548 | Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study. | 2020 Jun |
2 |
| 5 |
30657766 | Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. | 2019 |
1 |
| 6 |
30711950 | The C-Terminus of Hepatitis B Virus-encoded X Protein Is Required for Lapatinib Sensitivity in Hepatocellular Carcinoma Cells. | 2019 Feb |
2 |
| 7 |
31209328 | Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. | 2019 Jul |
1 |
| 8 |
29712619 | Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. | 2018 May 1 |
2 |
| 9 |
29963236 | Activating HER3 mutations in breast cancer. | 2018 Jun 12 |
1 |
| 10 |
29963251 | MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. | 2018 Jun 15 |
1 |
| 11 |
30023006 | Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer. | 2018 |
1 |
| 12 |
30057690 | HER3 signaling and targeted therapy in cancer. | 2018 Jan 30 |
1 |
| 13 |
28032592 | Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. | 2017 Jan 17 |
2 |
| 14 |
28873009 | 89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment. | 2017 Nov/Dec |
4 |
| 15 |
26581908 | Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. | 2016 May |
2 |
| 16 |
26595522 | HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. | 2016 Jan 5 |
1 |
| 17 |
26621843 | The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. | 2016 Jan 19 |
6 |
| 18 |
27474152 | ERBB2 Overexpression Establishes ERBB3-Dependent Hypersensitivity of Breast Cancer Cells to Withaferin A. | 2016 Nov |
1 |
| 19 |
27633099 | Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway. | 2016 Nov |
1 |
| 20 |
27768588 | Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. | 2016 Dec 20 |
1 |
| 21 |
25398453 | Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039). | 2015 Jul 1 |
2 |
| 22 |
25449780 | Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. | 2015 Jan 28 |
1 |
| 23 |
25619841 | Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. | 2015 Oct 8 |
1 |
| 24 |
25691057 | Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. | 2015 Mar 20 |
2 |
| 25 |
25865888 | Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. | 2015 Apr 21 |
2 |
| 26 |
25876877 | The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells. | 2015 Jul |
1 |
| 27 |
26181325 | Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. | 2015 |
1 |
| 28 |
26204261 | The Evolving Landscape of HER2 Targeting in Breast Cancer. | 2015 Nov |
1 |
| 29 |
26225238 | Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers. | 2015 Mar |
1 |
| 30 |
26296355 | Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas. | 2015 Dec 15 |
3 |
| 31 |
26484410 | Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. | 2015 Nov 3 |
1 |
| 32 |
24036211 | HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4). | 2014 Jan |
1 |
| 33 |
24492289 | Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. | 2014 Mar-Apr |
4 |
| 34 |
24520092 | Molecular pathways: HER3 targeted therapy. | 2014 Mar 15 |
1 |
| 35 |
24692179 | Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway. | 2014 Nov |
1 |
| 36 |
24711549 | Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. | 2014 May 10 |
1 |
| 37 |
24973425 | Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. | 2014 Sep 1 |
1 |
| 38 |
23233650 | An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). | 2013 Apr |
1 |
| 39 |
23292912 | ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. | 2013 Jul |
2 |
| 40 |
23378579 | The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression. | 2013 Apr |
1 |
| 41 |
23395887 | Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. | 2013 Apr |
1 |
| 42 |
23816254 | A gene expression profile indicative of early stage HER2 targeted therapy response. | 2013 Jul 1 |
1 |
| 43 |
23896512 | Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. | 2013 Aug |
1 |
| 44 |
23943608 | Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. | 2013 Aug 13 |
3 |
| 45 |
24014028 | Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. | 2013 Oct 18 |
1 |
| 46 |
24044505 | An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. | 2013 |
3 |
| 47 |
24112719 | Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells. | 2013 Dec |
3 |
| 48 |
22407832 | Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. | 2012 May 1 |
1 |
| 49 |
22461506 | HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. | 2012 May 15 |
1 |
| 50 |
22553357 | ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo. | 2012 Jul |
1 |